Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Cancer events in Belgian nursing home residents: An EORTC prospective cohort study.

Wildiers H, Mauer M, Elseviers M, De Wolf J, Hatse S, Hamaker M, Buntinx F, De Lepeleire J, Uytterschaut G, Falandry C, Tryfonidis K, Janssen-Heijnen M.

J Geriatr Oncol. 2019 Sep;10(5):805-810. doi: 10.1016/j.jgo.2019.03.005. Epub 2019 Mar 18.

2.

Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy.

Dalmasso B, Hatse S, Brouwers B, Laenen A, Berben L, Kenis C, Smeets A, Neven P, Schöffski P, Wildiers H.

BMC Cancer. 2018 Oct 22;18(1):1014. doi: 10.1186/s12885-018-4920-6.

3.

Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival.

Speigl L, Grieb A, Janssen N, Hatse S, Brouwers B, Smeets A, Floris G, Bailur JK, Kenis C, Neven P, Wildiers H, Pawelec G, Shipp C.

J Geriatr Oncol. 2018 Nov;9(6):606-612. doi: 10.1016/j.jgo.2018.03.021. Epub 2018 Apr 21.

PMID:
29685380
4.

The footprint of the ageing stroma in older patients with breast cancer.

Brouwers B, Fumagalli D, Brohee S, Hatse S, Govaere O, Floris G, Van den Eynde K, Bareche Y, Schöffski P, Smeets A, Neven P, Lambrechts D, Sotiriou C, Wildiers H.

Breast Cancer Res. 2017 Jul 3;19(1):78. doi: 10.1186/s13058-017-0871-0.

5.

Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty.

Bailur JK, Pawelec G, Hatse S, Brouwers B, Smeets A, Neven P, Laenen A, Wildiers H, Shipp C.

Breast Cancer Res. 2017 Feb 28;19(1):20. doi: 10.1186/s13058-017-0813-x.

6.

rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.

Liu J, Lončar I, Collée JM, Bolla MK, Dennis J, Michailidou K, Wang Q, Andrulis IL, Barile M, Beckmann MW, Behrens S, Benitez J, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Brauch H, Brennan P, Brenner H, Broeks A, Burwinkel B, Chang-Claude J, Chen ST, Chenevix-Trench G, Cheng CY, Choi JY, Couch FJ, Cox A, Cross SS, Cuk K, Czene K, Dörk T, Dos-Santos-Silva I, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Goldberg MS, González-Neira A, Guénel P, Haiman CA, Hamann U, Hart SN, Hartman M, Hatse S, Hopper JL, Ito H, Jakubowska A, Kabisch M, Kang D, Kosma VM, Kristensen VN, Le Marchand L, Lee E, Li J, Lophatananon A, Jan Lubinski, Mannermaa A, Matsuo K, Milne RL; NBCS Collaborators, Neuhausen SL, Nevanlinna H, Orr N, Perez JI, Peto J, Putti TC, Pylkäs K, Radice P, Sangrajrang S, Sawyer EJ, Schmidt MK, Schneeweiss A, Shen CY, Shrubsole MJ, Shu XO, Simard J, Southey MC, Swerdlow A, Teo SH, Tessier DC, Thanasitthichai S, Tomlinson I, Torres D, Truong T, Tseng CC, Vachon C, Winqvist R, Wu AH, Yannoukakos D, Zheng W, Hall P, Dunning AM, Easton DF, Hooning MJ, van den Ouweland AM, Martens JW, Hollestelle A.

Sci Rep. 2016 Nov 15;6:36874. doi: 10.1038/srep36874.

7.

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.

Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van Den Bulck H, Smeets A, Bechter O, Bailur JK, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem GE, Wildiers H.

Oncotarget. 2016 May 24;7(21):29977-88. doi: 10.18632/oncotarget.8796.

8.

Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.

Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H.

Breast Cancer Res Treat. 2015 Jul;152(1):67-76. doi: 10.1007/s10549-015-3437-9. Epub 2015 May 28.

PMID:
26017071
9.

Biological ageing and frailty markers in breast cancer patients.

Brouwers B, Dalmasso B, Hatse S, Laenen A, Kenis C, Swerts E, Neven P, Smeets A, Schöffski P, Wildiers H.

Aging (Albany NY). 2015 May;7(5):319-33.

10.

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.

Lei J, Rudolph A, Moysich KB, Rafiq S, Behrens S, Goode EL, Pharoah PP, Seibold P, Fasching PA, Andrulis IL, Kristensen VN, Couch FJ, Hamann U, Hooning MJ, Nevanlinna H, Eilber U, Bolla MK, Dennis J, Wang Q, Lindblom A, Mannermaa A, Lambrechts D, García-Closas M, Hall P, Chenevix-Trench G, Shah M, Luben R, Haeberle L, Ekici AB, Beckmann MW, Knight JA, Glendon G, Tchatchou S, Alnæs GI, Borresen-Dale AL, Nord S, Olson JE, Hallberg E, Vachon C, Torres D, Ulmer HU, Rüdiger T, Jager A, van Deurzen CH, Tilanus-Linthorst MM, Muranen TA, Aittomäki K, Blomqvist C, Margolin S, Kosma VM, Hartikainen JM, Kataja V, Hatse S, Wildiers H, Smeets A, Figueroa J, Chanock SJ, Lissowska J, Li J, Humphreys K, Phillips KA; kConFab Investigators, Linn S, Cornelissen S, van den Broek SA, Kang D, Choi JY, Park SK, Yoo KY, Hsiung CN, Wu PE, Hou MF, Shen CY, Teo SH, Taib NA, Yip CH, Ho GF, Matsuo K, Ito H, Iwata H, Tajima K, Dunning AM, Benitez J, Czene K, Sucheston LE, Maishman T, Tapper WJ, Eccles D, Easton DF, Schmidt MK, Chang-Claude J.

Breast Cancer Res. 2015 Feb 10;17:18. doi: 10.1186/s13058-015-0522-2.

11.

Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status.

Hatse S, Brouwers B, Dalmasso B, Laenen A, Kenis C, Schöffski P, Wildiers H.

PLoS One. 2014 Oct 21;9(10):e110644. doi: 10.1371/journal.pone.0110644. eCollection 2014.

12.

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.

Vulsteke C, Pfeil AM, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Peeters M, van Dam P, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H.

Breast Cancer Res Treat. 2014 Oct;147(3):557-70. doi: 10.1007/s10549-014-3105-5. Epub 2014 Aug 29.

PMID:
25168315
13.

Genetic predisposition to in situ and invasive lobular carcinoma of the breast.

Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, Fletcher O, Pinder S, Hanby A, Kohut K, Gorman P, Caneppele M, Peto J, Dos Santos Silva I, Johnson N, Swann R, Dwek M, Perkins KA, Gillett C, Houlston R, Ross G, De Ieso P, Southey MC, Hopper JL, Provenzano E, Apicella C, Wesseling J, Cornelissen S, Keeman R, Fasching PA, Jud SM, Ekici AB, Beckmann MW, Kerin MJ, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Kerbrat P, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Perez JI, Menéndez P, Benitez J, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler RK, Lochmann M, Brauch H, Fischer HP, Ko YD; GENICA Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Chenevix-Trench G, Investigators K, Lambrechts D, Weltens C, Van Limbergen E, Hatse S, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Volorio S, Giles GG, Severi G, Baglietto L, McLean CA, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Kristensen V, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Devillee P, Tollenaar RA, Seynaeve CM, Kriege M, Figueroa J, Chanock SJ, Sherman ME, Hooning MJ, Hollestelle A, van den Ouweland AM, van Deurzen CH, Li J, Czene K, Humphreys K, Cox A, Cross SS, Reed MW, Shah M, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Couch FJ, Hallberg E, González-Neira A, Pita G, Alonso MR, Tessier DC, Vincent D, Bacot F, Bolla MK, Wang Q, Dennis J, Michailidou K, Dunning AM, Hall P, Easton D, Pharoah P, Schmidt MK, Tomlinson I, Garcia-Closas M.

PLoS Genet. 2014 Apr 17;10(4):e1004285. doi: 10.1371/journal.pgen.1004285. eCollection 2014 Apr.

14.

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.

Pfeil AM, Vulsteke C, Paridaens R, Dieudonné AS, Pettengell R, Hatse S, Neven P, Lambrechts D, Szucs TD, Schwenkglenks M, Wildiers H.

BMC Cancer. 2014 Mar 19;14:201. doi: 10.1186/1471-2407-14-201.

15.

Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging?

Pallis AG, Hatse S, Brouwers B, Pawelec G, Falandry C, Wedding U, Lago LD, Repetto L, Ring A, Wildiers H.

J Geriatr Oncol. 2014 Apr;5(2):204-18. doi: 10.1016/j.jgo.2013.09.001. Epub 2013 Sep 29. Review.

PMID:
24495695
16.

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).

Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, Wildiers H.

Ann Oncol. 2013 Jun;24(6):1513-25. doi: 10.1093/annonc/mdt008. Epub 2013 Feb 7.

PMID:
23396606
17.

Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.

Kirchhoff T, Gaudet MM, Antoniou AC, McGuffog L, Humphreys MK, Dunning AM, Bojesen SE, Nordestgaard BG, Flyger H, Kang D, Yoo KY, Noh DY, Ahn SH, Dork T, Schürmann P, Karstens JH, Hillemanns P, Couch FJ, Olson J, Vachon C, Wang X, Cox A, Brock I, Elliott G, Reed MW, Burwinkel B, Meindl A, Brauch H, Hamann U, Ko YD; GENICA Network, Broeks A, Schmidt MK, Van 't Veer LJ, Braaf LM, Johnson N, Fletcher O, Gibson L, Peto J, Turnbull C, Seal S, Renwick A, Rahman N, Wu PE, Yu JC, Hsiung CN, Shen CY, Southey MC, Hopper JL, Hammet F, Van Dorpe T, Dieudonne AS, Hatse S, Lambrechts D, Andrulis IL, Bogdanova N, Antonenkova N, Rogov JI, Prokofieva D, Bermisheva M, Khusnutdinova E, van Asperen CJ, Tollenaar RA, Hooning MJ, Devilee P, Margolin S, Lindblom A, Milne RL, Arias JI, Zamora MP, Benítez J, Severi G, Baglietto L, Giles GG; kConFab; AOCS Study Group, Spurdle AB, Beesley J, Chen X, Holland H, Healey S, Wang-Gohrke S, Chang-Claude J, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Agnarsson BA, Caligo MA, Godwin AK, Nevanlinna H, Heikkinen T, Fredericksen Z, Lindor N, Nathanson KL, Domchek SM; SWE-BRCA, Loman N, Karlsson P, Stenmark Askmalm M, Melin B, von Wachenfeldt A; HEBON, Hogervorst FB, Verheus M, Rookus MA, Seynaeve C, Oldenburg RA, Ligtenberg MJ, Ausems MG, Aalfs CM, Gille HJ, Wijnen JT, Gómez García EB; EMBRACE, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Pichert G, Davidson R, Chu C, Eccles D, Ong KR, Cook J, Douglas F, Hodgson S, Evans DG, Eeles R, Gold B, Pharoah PD, Offit K, Chenevix-Trench G, Easton DF; BCAC/CIMBA.

PLoS One. 2012;7(6):e35706. doi: 10.1371/journal.pone.0035706. Epub 2012 Jun 29.

18.

Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency.

Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, Brouckaert O, Peuteman G, Laenen A, Verlinden L, Kriebitzsch C, Dieudonné AS, Paridaens R, Neven P, Christiaens MR, Bouillon R, Wildiers H.

Carcinogenesis. 2012 Jul;33(7):1319-26. doi: 10.1093/carcin/bgs187. Epub 2012 May 23.

PMID:
22623648
19.

The role of genetic breast cancer susceptibility variants as prognostic factors.

Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, van't Veer LJ, Udo R, Dunning AM, Greco D, Aittomäki K, Blomqvist C, Shah M, Nordestgaard BG, Flyger H, Hopper JL, Southey MC, Apicella C, Garcia-Closas M, Sherman M, Lissowska J, Seynaeve C, Huijts PE, Tollenaar RA, Ziogas A, Ekici AB, Rauh C, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Andrulis IL, Ozcelik H, Mulligan AM, Glendon G, Hall P, Czene K, Liu J, Chang-Claude J, Wang-Gohrke S, Eilber U, Nickels S, Dörk T, Schiekel M, Bremer M, Park-Simon TW, Giles GG, Severi G, Baglietto L, Hooning MJ, Martens JW, Jager A, Kriege M, Lindblom A, Margolin S, Couch FJ, Stevens KN, Olson JE, Kosel M, Cross SS, Balasubramanian SP, Reed MW, Miron A, John EM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Chenevix-Trench G; kConFab Investigators, Lambrechts D, Dieudonne AS, Hatse S, van Limbergen E, Benitez J, Milne RL, Zamora MP, Pérez JI, Bonanni B, Peissel B, Loris B, Peterlongo P, Rajaraman P, Schonfeld SJ, Anton-Culver H, Devilee P, Beckmann MW, Slamon DJ, Phillips KA, Figueroa JD, Humphreys MK, Easton DF, Schmidt MK.

Hum Mol Genet. 2012 Sep 1;21(17):3926-39. doi: 10.1093/hmg/dds159. Epub 2012 Apr 24.

20.

19p13.1 is a triple-negative-specific breast cancer susceptibility locus.

Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, Nevanlinna H, Greco D, Aittomäki K, Blomqvist C, Chang-Claude J, Vrieling A, Flesch-Janys D, Sinn HP, Wang-Gohrke S, Nickels S, Brauch H; GENICA Network, Ko YD, Fischer HP, Schmutzler RK, Meindl A, Bartram CR, Schott S, Engel C, Godwin AK, Weaver J, Pathak HB, Sharma P, Brenner H, Müller H, Arndt V, Stegmaier C, Miron P, Yannoukakos D, Stavropoulou A, Fountzilas G, Gogas HJ, Swann R, Dwek M, Perkins A, Milne RL, Benítez J, Zamora MP, Pérez JI, Bojesen SE, Nielsen SF, Nordestgaard BG, Flyger H, Guénel P, Truong T, Menegaux F, Cordina-Duverger E, Burwinkel B, Marmé F, Schneeweiss A, Sohn C, Sawyer E, Tomlinson I, Kerin MJ, Peto J, Johnson N, Fletcher O, Dos Santos Silva I, Fasching PA, Beckmann MW, Hartmann A, Ekici AB, Lophatananon A, Muir K, Puttawibul P, Wiangnon S, Schmidt MK, Broeks A, Braaf LM, Rosenberg EH, Hopper JL, Apicella C, Park DJ, Southey MC, Swerdlow AJ, Ashworth A, Orr N, Schoemaker MJ, Anton-Culver H, Ziogas A, Bernstein L, Dur CC, Shen CY, Yu JC, Hsu HM, Hsiung CN, Hamann U, Dünnebier T, Rüdiger T, Ulmer HU, Pharoah PP, Dunning AM, Humphreys MK, Wang Q, Cox A, Cross SS, Reed MW, Hall P, Czene K, Ambrosone CB, Ademuyiwa F, Hwang H, Eccles DM, Garcia-Closas M, Figueroa JD, Sherman ME, Lissowska J, Devilee P, Seynaeve C, Tollenaar RA, Hooning MJ, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, John EM, Miron A, Alnæs GG, Kristensen V, Børresen-Dale AL, Giles GG, Baglietto L, McLean CA, Severi G, Kosel ML, Pankratz VS, Slager S, Olson JE, Radice P, Peterlongo P, Manoukian S, Barile M, Lambrechts D, Hatse S, Dieudonne AS, Christiaens MR, Chenevix-Trench G; kConFab Investigators; AOCS Group, Beesley J, Chen X, Mannermaa A, Kosma VM, Hartikainen JM, Soini Y, Easton DF, Couch FJ.

Cancer Res. 2012 Apr 1;72(7):1795-803. doi: 10.1158/0008-5472.CAN-11-3364. Epub 2012 Feb 13.

21.

CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization.

Liekens S, Schols D, Hatse S.

Curr Pharm Des. 2010;16(35):3903-20. Review.

PMID:
21158728
22.

Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.

Skerlj RT, Bridger GJ, Kaller A, McEachern EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D, Wilson T, Harwig C, Hatse S, Princen K, De Clercq E, Schols D.

J Med Chem. 2010 Apr 22;53(8):3376-88. doi: 10.1021/jm100073m.

PMID:
20297846
23.

Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.

Bridger GJ, Skerlj RT, Hernandez-Abad PE, Bogucki DE, Wang Z, Zhou Y, Nan S, Boehringer EM, Wilson T, Crawford J, Metz M, Hatse S, Princen K, De Clercq E, Schols D.

J Med Chem. 2010 Feb 11;53(3):1250-60. doi: 10.1021/jm901530b.

PMID:
20043638
24.

Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.

Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ, Schwartz TW.

J Biol Chem. 2007 Sep 14;282(37):27354-65. Epub 2007 Jun 28.

25.

Modest human immunodeficiency virus coreceptor function of CXCR3 is strongly enhanced by mimicking the CXCR4 ligand binding pocket in the CXCR3 receptor.

Hatse S, Huskens D, Princen K, Vermeire K, Bridger GJ, De Clercq E, Rosenkilde MM, Schwartz TW, Schols D.

J Virol. 2007 Apr;81(7):3632-9. Epub 2007 Jan 24.

26.

The nucleotide analog cidofovir suppresses basic fibroblast growth factor (FGF2) expression and signaling and induces apoptosis in FGF2-overexpressing endothelial cells.

Liekens S, Gijsbers S, Vanstreels E, Daelemans D, De Clercq E, Hatse S.

Mol Pharmacol. 2007 Mar;71(3):695-703. Epub 2006 Dec 7.

PMID:
17158200
27.

Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Balzarini J, Van Laethem K, Daelemans D, Hatse S, Bugatti A, Rusnati M, Igarashi Y, Oki T, Schols D.

J Virol. 2007 Jan;81(1):362-73. Epub 2006 Oct 18.

28.

Stromal cell-derived factor 1 (CXCL12) binds to endothelial cells and signals through a receptor different from CXCR4.

Hatse S, Balzarini J, Liekens S.

Biochem Biophys Res Commun. 2006 Sep 15;348(1):192-9. Epub 2006 Jul 17.

PMID:
16875673
29.

Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis.

De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, Vermeire K, Bridger G, Billiau A, Schols D, Matthys P.

Arthritis Res Ther. 2005;7(6):R1208-20. Epub 2005 Aug 25.

30.

Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the achilles heel of HIV.

Balzarini J, Van Laethem K, Hatse S, Froeyen M, Peumans W, Van Damme E, Schols D.

J Biol Chem. 2005 Dec 9;280(49):41005-14. Epub 2005 Sep 23.

31.

AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.

Hatse S, Princen K, De Clercq E, Rosenkilde MM, Schwartz TW, Hernandez-Abad PE, Skerlj RT, Bridger GJ, Schols D.

Biochem Pharmacol. 2005 Sep 1;70(5):752-61.

PMID:
16011832
32.

Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.

Balzarini J, Van Laethem K, Hatse S, Froeyen M, Van Damme E, Bolmstedt A, Peumans W, De Clercq E, Schols D.

Mol Pharmacol. 2005 May;67(5):1556-65. Epub 2005 Feb 17.

PMID:
15718224
33.

CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.

Vermeire K, Princen K, Hatse S, De Clercq E, Dey K, Bell TW, Schols D.

AIDS. 2004 Nov 5;18(16):2115-25.

PMID:
15577644
34.

Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.

Princen K, Hatse S, Vermeire K, Aquaro S, De Clercq E, Gerlach LO, Rosenkilde M, Schwartz TW, Skerlj R, Bridger G, Schols D.

J Virol. 2004 Dec;78(23):12996-3006.

35.

Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection.

Balzarini J, Hatse S, Vermeire K, Princen K, Aquaro S, Perno CF, De Clercq E, Egberink H, Vanden Mooter G, Peumans W, Van Damme E, Schols D.

Antimicrob Agents Chemother. 2004 Oct;48(10):3858-70.

36.

Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.

Hatse S, Princen K, Liekens S, Vermeire K, De Clercq E, Schols D.

Cytometry A. 2004 Oct;61(2):178-88.

37.

Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins.

Balzarini J, Van Laethem K, Hatse S, Vermeire K, De Clercq E, Peumans W, Van Damme E, Vandamme AM, Bölmstedt A, Schols D.

J Virol. 2004 Oct;78(19):10617-27. Erratum in: J Virol.2004 Nov;78(2):12724. Böhlmstedt, Anders [corrected to Bölmstedt, Anders].

39.

X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction.

Hatse S, Bridger G, de Clercq E, Schols D.

Cell Mol Biol (Noisy-le-grand). 2003;49 Online Pub:OL443-52.

PMID:
14995074
40.

Human herpesvirus 6 infection arrests cord blood mononuclear cells in G(2) phase of the cell cycle.

De Bolle L, Hatse S, Verbeken E, De Clercq E, Naesens L.

FEBS Lett. 2004 Feb 27;560(1-3):25-9.

41.

The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.

Princen K, Hatse S, Vermeire K, Bridger GJ, Skerlj RT, De Clercq E, Schols D.

AIDS Res Hum Retroviruses. 2003 Dec;19(12):1135-9.

PMID:
14709250
42.

Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry.

Hatse S, Princen K, Vermeire K, Gerlach LO, Rosenkilde MM, Schwartz TW, Bridger G, De Clercq E, Schols D.

FEBS Lett. 2003 Jul 10;546(2-3):300-6.

43.

Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry.

Princen K, Hatse S, Vermeire K, De Clercq E, Schols D.

Cytometry A. 2003 Jan;51(1):35-45.

44.

CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor.

Vermeire K, Zhang Y, Princen K, Hatse S, Samala MF, Dey K, Choi HJ, Ahn Y, Sodoma A, Snoeck R, Andrei G, De Clercq E, Bell TW, Schols D.

Virology. 2002 Oct 25;302(2):342-53.

45.

Role of MRP4 and MRP5 in biology and chemotherapy.

Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, Matherly LH, Schuetz JD.

AAPS PharmSci. 2002;4(3):E14. Review.

46.

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

Hatse S, Princen K, Bridger G, De Clercq E, Schols D.

FEBS Lett. 2002 Sep 11;527(1-3):255-62.

47.

AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.

Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW, De Clercq E, Billiau A, Schols D.

J Immunol. 2001 Oct 15;167(8):4686-92.

48.

Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.

Hatse S, Princen K, Gerlach LO, Bridger G, Henson G, De Clercq E, Schwartz TW, Schols D.

Mol Pharmacol. 2001 Jul;60(1):164-73.

PMID:
11408611
50.

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.

Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P.

Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7476-81.

Supplemental Content

Support Center